#PLOS ONE

A new type of syringe apparently falls short at lowering the risk of hepatitis C virus transmission.

While many of those seeking insurance coverage for hepatitis C treatment may be initially denied, this decision may still be reversible upon a...

The World Health Organization has called for all hospitals and clinics worldwide to use ’smart syringes,’ which prevent a second use, by 2020.

Programs that seek to discourage the sharing of drug injection equipment can also lower the risk of hepatitis C by encouraging less frequent s...

Treatment outcome and survival is similar between those with hepatitis B- and hepatitis C-related liver cancer, although those with advanced t...

People with hepatitis B and cirrhosis should be prioritized for liver cancer screening, which is cost-effective among this population.

A comprehensive harm reduction program instituted by the Scottish government has sharply reduced hepatitis C rates among injection drug users.

Only half of Americans living with hepatitis C are aware of their infection, and just 9 percent of the total have been cured of the virus.

Nearly 50 percent of people living with hepatitis C in the U.S. are unaware of their infection and less than 10 percent have been effectively...

The HIV antiretroviral Viread (tenofovir) is highly effective in combating both HIV and hepatitis B among those coinfected with both viruses